Evaluation of Faecal Elastase 1 in Symptomatic Patients with Neuroendocrine Tumours Abstract #1837

Introduction: There is limited data on exocrine pancreatic insufficiency in patients on somatostatin analogues(SSA) which affects quality of life in NETs.
Aim(s): We explored the value of faecal elastase(FE) as a marker of exocrine pancreatic insufficiency in patients with NETs.
Materials and methods: 39 patients (27 midgut,5 pancreatic,7 other) consecutively referred to a gastroenterology NET clinic completed standardised questionnaires regarding symptoms and quality of life (QoL) as part of clinical care. FE was prospectively evaluated to investigate steatorrhoea.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Dr Mohid Khan

To read results and conclusion, please login ...

Further abstracts you may be interested in

#43 Relationship between neuroendocrine tumor-related symptoms and RAND-36 health-related quality of life scores
Introduction: Neuroendocrine tumors (NETs) can secrete hormones that cause flushing and diarrhea (carcinoid syndrome) and disrupt health-related quality of life (HRQL).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Beaumont J L, Liu Z, Choi S, Yao J C, ...
#1470 Exploring Gastrointestinal Symptoms And Their Impact on Quality of Life in Patients with Neuroendocrine Tumours
Introduction: Treatments in NETs have been studied for effects on tumour progression and carcinoid syndrome with minimal evidence on gastrointestinal(GI) symptom burden and impact on quality of life(QoL)
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Dr Mohid Khan
Authors: Williams M, Reid K, Ng S, Benny A, ...
#1835 A Prospective Service Evaluation of Systematic Gastroenterological Assessment and Management on Patients with Neuroendocrine Tumours in South East Wales
Introduction: Patients with NETs can experience gastrointestinal(GI) symptoms including diarrhoea, steatorrhoea and urgency.
Conference: 14th Annual ENETS conference (2017)
Category: ...none of the above
Presenting Author: Dr Mohid Khan
#2025 Health-Related Quality of Life Determinants in Swedish Patients after Surgery for Small Intestinal Neuroendocrine Tumors
Introduction: Overall survival for patients with small intestinal neuroendocrine tumors (siNETs) is often long even with metastatic disease, making quality of life issues especially relevant. The impact of surgery on their quality of life is unknown.
Conference: 15th Annual ENETS conference (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Anna Caterina Milanetto
#1676 NETTER-1 Phase III Trial: Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors
Introduction: Impairment in quality of life caused by tumor load and hormone-related symptoms is frequent in GEP-NET patients. In the Phase III NETTER-1 trial, patients with advanced, progressive midgut NETs were randomized to treatment with 177Lu-DOTATATE (177Lu; Lutathera®) or high-dose (60 mg) Octreotide LAR (Oct).
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Prof. Jonathan Strosberg
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.